{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:16:17Z","timestamp":1762506977934,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.jsat.2016.12.002","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T12:33:18Z","timestamp":1481718798000},"page":"7-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians"],"prefix":"10.1016","volume":"74","author":[{"given":"Maximilian","family":"Gahr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Eller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice","family":"Cabanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Hiemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland W.","family":"Freudenmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard J.","family":"Connemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6912-4843","authenticated-orcid":false,"given":"Dirk","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Sch\u00f6nfeldt-Lecuona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2016.12.002_bb0005","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: A randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2016.12.002_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bcp.12051","article-title":"Pharmacological maintenance treatment of opiate addiction","volume":"77","author":"Bell","year":"2014","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jsat.2016.12.002_bb0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/00002018-200022030-00002","article-title":"A risk-benefit analysis of methadone maintenance treatment","volume":"22","author":"Bell","year":"2000","journal-title":"Drug Safety"},{"key":"10.1016\/j.jsat.2016.12.002_bb0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/09595230412331289473","article-title":"A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence","volume":"23","author":"Bell","year":"2004","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.jsat.2016.12.002_bb0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Safety"},{"key":"10.1016\/j.jsat.2016.12.002_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis","year":"2012","journal-title":"The Journal of Supportive Oncology"},{"key":"10.1016\/j.jsat.2016.12.002_bb0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11096-012-9675-6","article-title":"Attitudes of Portugese health professionals towards adverse drug reaction reporting","volume":"34","author":"dos Santos Pernas","year":"2012","journal-title":"International Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jsat.2016.12.002_bb0040","first-page":"CD003410","article-title":"Heroin maintenance for chronic heroin-dependent individuals","volume":"12","author":"Ferri","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.jsat.2016.12.002_bb0045","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2165\/11204760-000000000-00000","article-title":"Escitalopram: A review of its use in the management of major depressive disorder in adults","volume":"24","author":"Garnock-Jones","year":"2010","journal-title":"CNS Drugs"},{"year":"2013","series-title":"Daten des Gesundheitswesen","author":"Gesundheit","key":"10.1016\/j.jsat.2016.12.002_bb0050"},{"key":"10.1016\/j.jsat.2016.12.002_bb0055","first-page":"405","article-title":"Take home maintenance medication in opiate dependence","volume":"110","author":"Gutwinski","year":"2013","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"10.1016\/j.jsat.2016.12.002_bb0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(07)61273-2","article-title":"Clinical update: Codeine maintenance in opioid dependence","volume":"370","author":"Hall","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2016.12.002_bb0065","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","article-title":"Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions","volume":"55","author":"Hasford","year":"2002","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1016\/j.jsat.2016.12.002_bb0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: A systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Safety"},{"key":"10.1016\/j.jsat.2016.12.002_bb0075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: Norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jsat.2016.12.002_bb0080","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2165\/00002018-200730110-00006","article-title":"Factors that influence under-reporting of suspected adverse drug reactions among community pharmacists in a Spanish region","volume":"30","author":"Irujo","year":"2007","journal-title":"Drug Safety"},{"issue":"Suppl. 3","key":"10.1016\/j.jsat.2016.12.002_bb0085","first-page":"291S","article-title":"Mixed agonist-antagonist opiates and physical dependence","volume":"7","author":"Jacob","year":"1979","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jsat.2016.12.002_bb0090","first-page":"347","article-title":"Methadone maintenance treatment (MMT): A review of historical and clinical issues","volume":"67","author":"Joseph","year":"2000","journal-title":"The Mount Sinai Journal of Medicine"},{"key":"10.1016\/j.jsat.2016.12.002_bb0095","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cpt1976204445","article-title":"Side effects of levomethadone and racemic methadone in a maintenance program","volume":"20","author":"Judson","year":"1976","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.jsat.2016.12.002_bb0100","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/add.13013","article-title":"Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration","volume":"110","author":"Kao","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2016.12.002_bb0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev.publhealth.28.021406.144059","article-title":"New challenges for telephone survey research in the twenty-first century","volume":"28","author":"Kempf","year":"2007","journal-title":"Annual Review of Public Health"},{"key":"10.1016\/j.jsat.2016.12.002_bb0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/0976-9668.107289","article-title":"Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: An observational study","volume":"4","author":"Khan","year":"2013","journal-title":"Journal Natural Science Biology Medicine"},{"key":"10.1016\/j.jsat.2016.12.002_bb0115","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/bph.12796","article-title":"BU08073 a buprenorphine analogue with partial agonist activity at u-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice","volume":"172","author":"Khroyan","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.jsat.2016.12.002_bb0120","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpain.2008.04.011","article-title":"Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine","volume":"13","author":"Kress","year":"2009","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.jsat.2016.12.002_bb0125","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jsat.2016.12.002_bb0130","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1517\/14656566.2014.955469","article-title":"Buprenorphine in the treatment of opioid addiction: Opportunities, challenges and strategies","volume":"15","author":"Li","year":"2014","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.jsat.2016.12.002_bb0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: A systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Safety"},{"key":"10.1016\/j.jsat.2016.12.002_bb0140","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.317.7151.119","article-title":"Underreporting of suspected adverse drug reactions to newly marketed (\u201cblack triangle\u201d) drugs in general practice: Observational study","volume":"317","author":"Martin","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jsat.2016.12.002_bb0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S1092852913000229","article-title":"Pharmacotherapies for treating opioid use disorders","volume":"18","author":"Nguyen","year":"2013","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.jsat.2016.12.002_bb0150","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1001\/jama.1988.03720220045024","article-title":"Methadone maintenance patients in general medical practice. A preliminary report","volume":"259","author":"Novick","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.jsat.2016.12.002_bb0155","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550887.2015.1059225","article-title":"Methadone medical maintenance: An early 21st-century perspective","volume":"34","author":"Novick","year":"2015","journal-title":"Journal of Addictive Diseases"},{"key":"10.1016\/j.jsat.2016.12.002_bb0160","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jsat.2010.03.003","article-title":"Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: A pilot study","volume":"38","author":"Oviedo-Joekes","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2016.12.002_bb0165","first-page":"24","article-title":"A study of the sexual function, sleep, and weight status of patients after 6months of methadone maintenance treatment","volume":"7","author":"Parvaresh","year":"2015","journal-title":"Addiction and Health"},{"key":"10.1016\/j.jsat.2016.12.002_bb0170","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/pds.2193","article-title":"The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: Direct survey among health professionals","volume":"20","author":"P\u00e9rez Garc\u00eda","year":"2011","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.jsat.2016.12.002_bb0175","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacologic profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Practice"},{"key":"10.1016\/j.jsat.2016.12.002_bb0180","article-title":"Opioid dependence","author":"Praveen","year":"2011","journal-title":"BMJ Clinical Evidence"},{"key":"10.1016\/j.jsat.2016.12.002_bb0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000351784","article-title":"Psychiatric comorbidity and personality structure in patients with polyvalent addiction","volume":"47","author":"Rentrop","year":"2014","journal-title":"Psychopathology"},{"key":"10.1016\/j.jsat.2016.12.002_bb0190","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1527-3458.2002.tb00235.x","article-title":"Buprenorphine: An analgesic with an expanding role in the treatment of opioid addiction","volume":"8","author":"Robinson","year":"2002","journal-title":"CNS Drug Reviews"},{"key":"10.1016\/j.jsat.2016.12.002_bb0195","first-page":"1","article-title":"Knowledge about adverse drug reactions reporting among healthcare professionals in Nepal","volume":"25","author":"Santosh","year":"2013","journal-title":"The International Journal of Risk & Safety in Medicine"},{"key":"10.1016\/j.jsat.2016.12.002_bb0200","first-page":"82","article-title":"Methadone and levomethadone \u2014 Dosage and side effects","volume":"41","author":"Schoofs","year":"2014","journal-title":"Psychiatrische Praxis"},{"key":"10.1016\/j.jsat.2016.12.002_bb0205","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0253-7613.150344","article-title":"Under-reporting of adverse drug reactions: A challenge for pharmacovigilance in India","volume":"47","author":"Tandon","year":"2015","journal-title":"Indian Journal Pharmacology"},{"issue":"2 Suppl","key":"10.1016\/j.jsat.2016.12.002_bb0210","first-page":"S5","article-title":"Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) guidelines","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Physician"},{"key":"10.1016\/j.jsat.2016.12.002_bb0215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.drugalcdep.2005.04.007","article-title":"The effects of racemic d,l-methadone and l-methadone in substituted patients\u2014A randomized controlled study","volume":"80","author":"Verthein","year":"2005","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2016.12.002_bb0220","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/02791072.2010.10400689","article-title":"Buprenorphine in the treatment of opiate dependence","volume":"42","author":"Wesson","year":"2010","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1016\/j.jsat.2016.12.002_bb0225","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2217\/pmt.12.22","article-title":"Systematic review of adverse events of buprenorphine patch versus fentanyl patch in patients with chronic moderate-to-severe pain","volume":"2","author":"Wolff","year":"2012","journal-title":"Pain Management"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216302483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547216302483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:45:13Z","timestamp":1760039113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547216302483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":45,"alternative-id":["S0740547216302483"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2016.12.002","relation":{},"ISSN":["0740-5472"],"issn-type":[{"type":"print","value":"0740-5472"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2016.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}